Rabeprazole
- Generic Name
- Rabeprazole
- Brand Names
- Aciphex, Pariet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N3O3S
- CAS Number
- 117976-89-3
- Unique Ingredient Identifier
- 32828355LL
- Background
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
- Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Non-erosive Reflux Esophagitis Disease (NERD), Vomiting, Zollinger-Ellison Syndrome, Develop NSAID-induced gastric ulcers, Erosive reflux esophagitis
- Associated Therapies
- -
Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food
- Conditions
- Interventions
- First Posted Date
- 2014-03-27
- Last Posted Date
- 2014-06-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 27
- Registration Number
- NCT02097329
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)
- Conditions
- Interventions
- First Posted Date
- 2014-01-16
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT02037477
A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib
- Conditions
- Interventions
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT01772290
Effects of YF476 and Rabeprazole on Gastric Function
- Conditions
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2012-10-03
- Lead Sponsor
- Trio Medicines Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT01699113
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
Narrow-band Imaging, Autofluorescence Imaging and Gastroesophageal Reflux Disease
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 95
- Registration Number
- NCT01504971
- Locations
- 🇨🇳
Outpatient Department Building, Beijing, Beijing, China
ASP (PPI_H2RA) Study-H2RA Versus PPI for the Prevention of Recurrent UGIB in High-risk Users of Low-dose ASA
- Conditions
- Interventions
- First Posted Date
- 2011-08-03
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 264
- Registration Number
- NCT01408186
- Locations
- 🇯🇵
Department of Gastroenterology, Osaka City General Hospital, Osaka, Japan (Satellite hospital of Osaka City University), Osaka, Japan
🇯🇵Department of Internal Medicine and Gastroenterology, Saga Medical School, Saga, Japan, Saga, Japan
🇯🇵Second Department of Internal Medicine, Osaka Medical College, Takatsuki, Osaka, Japan, Osaka, Japan
Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
- Conditions
- Interventions
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 405
- Registration Number
- NCT01398410
Double-dose Rabeprazole Accelerates and Sustains the Control of Symptoms in Patients With NERD
- Conditions
- Interventions
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2012-01-18
- Lead Sponsor
- Inje University
- Registration Number
- NCT01391715
- Locations
- 🇰🇷
Haeundae Paik Hospital, Inje University School of Medicine, Busan, Korea, Republic of
Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis
- First Posted Date
- 2011-03-23
- Last Posted Date
- 2023-07-24
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 2157
- Registration Number
- NCT01321567
A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT01287091
- Locations
- 🇺🇸
Investigational Site, Austin, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.